The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

GLP-1 receptor agonists promote weight loss, which is a goal for many patients.” Despite the FDA approval of several GLP-1 ...

Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeekHigh Quality Obesity Management by Targeting the CRF2 Receptor ... Current GLP-1-based obesity medications ...

GLP-1 receptor agonists are widely prescribed for managing T2DM ... Notably, levels returned to normal after discontinuation, suggesting that such increases can be drug-related. This is the first ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...